LATEST NEWS

The US Food and Drug Administration has approved Besponsa for the Treatment of Refractory B-cell Precursor Acute Lymphoblastic Leukemia

(August 22, 2017)

Besponsa (Inotuzumab ozogamicin) is a targeted therapy designed to bind to B-cell acute lymphoblastic leukemia (ALL) cancer cells that express the CD22 antigen. Acute lymphoblastic leukemia comprises approximately... Continue Reading

U.S. FDA Removes Clinical Hold on CEL-SCI’s Phase 3 Head & Neck Cancer Trial

(August 21, 2017)

CEL-SCI Corporation today announced it has received a letter from the U.S. Food and Drug Administration (FDA) stating that the clinical hold that had been imposed on the Company’s Phase 3 cancer study... Continue Reading

Cervical Cancer Survivors Frequently Suffer From Long-Term Side Effects of Treatment

(August 17, 2017)

According to a new study around half of women who have been treated for locally advanced cervical cancer suffer from symptoms of insomnia, fatigue or hot flushes.1 Cervical cancer affects more than 500,000... Continue Reading

Alternative Medicine Used Alone Appears to Reduce Survival Rates in Cancer Patients

(August 16, 2017)

Patients who choose to receive alternative therapy as treatment for curable cancers instead of conventional cancer treatment have a higher risk of death, according to researchers from the Cancer Outcomes,... Continue Reading

REFERENCE AND TOOLS
LOCATIONS
Jackson Oncology Associates, PLLC
The Hederman Cancer Center
1227 North State Street, Suite 101
Jackson, MS 39202
TEL: (601)355-2485
FAX: (601)353-1463
Click Here for Map

Jackson Oncology Associates, PLLC
2368 Grove Street
Vicksburg, MS 39180
TEL: (601)638-3447
FAX: (601)630-9227
Click Here for Map
Jackson Oncology Associates, PLLC
St. Dominic Cancer Center
2969 Curran Drive North, Suite 200
TEL: (601)974-5600
FAX: (601)974-5699
Click Here for Map



Jackson Oncology Associates, PLLC
King's Daughters Hospital
427 Highway 51 North
Brookhaven, MS 39601
TEL: (601)355-2495
Click Here for Map